Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma.
Immunotherapy
; 10(5): 411-421, 2018 04.
Article
en En
| MEDLINE
| ID: mdl-29473472
ABSTRACT
Hepatocellular carcinoma (HCC) is a worldwide common malignancy with poor prognosis. Several studies have aimed at identification of appropriate biomarkers for early detection of this cancer. Cancer-testis antigens (CTAs) as a novel group of tumor-associated antigens have been demonstrated to be expressed in HCC samples as well as peripheral blood samples from these patients but not in the corresponding adjacent noncancerous samples. Such pattern of expression has provided them an opportunity to be used as immunotherapeutic targets. The detection of spontaneous immune responses against CTAs in HCC patients has prompted design of CTA-based immunotherapeutic protocols in these patients. The results of some clinical trials have been promising in a subset of patients.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma Hepatocelular
/
Inmunoterapia
/
Neoplasias Hepáticas
/
Antígenos de Neoplasias
Tipo de estudio:
Guideline
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Immunotherapy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Irán